MICB and hematopoietic and lymphoid cell neoplasm: The study of the immunomodulatory effects of different DHAs was expanded by qRT-PCR analysis of changes in the expression of selected immunostimulatory molecules (e.g., CXCL10 and CXCL9, MICA and MICB) in melanoma (n = 14) and hematological tumor (n = 10) cell lines treated with 1 μM guadecitabine, DAC or AZA.